Sanofi US News

"AF Stat(TM) Call to Action for Atrial Fibrillation" Report Cites Limited Understanding, Disconnected Dialogue and Uncoordinated Care as Key Barriers to Improved Outcomes

Influenza A (H1N1) 2009 Monovalent Vaccine licensure a key U.S. milestone in preparing for pandemic response this Fall

Approval Includes Use in Patients Two Years and Older with Seasonal Nasal Allergies Which Affect Forty Percent of Children in the U.S.

New York City Proclaims August 20, 2009 “Pertussis Awareness Day”

- Prophylaxis with Lovenox® (enoxaparin sodium injection) offered a cost reduction per discharge -

Company responds to FDA recommendation for influenza virus strain change supplement

Early shipment of vaccine to assist public health in immunization planning

Leading international experts conclude that these analyses present inconclusive and conflicting data

Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - - U.S. commercial launch planned for the summer of 2009

The CDC Reinstates Booster Dose of Hib Vaccine

Christopher A. Viehbacher Reaffirmed Sanofi-aventis’ Commitment to Access to Health during the Pacific Health Summit in Seattle

A1C and FBG Results for Patients 65 and Under Treated with Lantus and NPH were Similar

Study Presented at 69th Annual ADA Scientific Sessions Examined Efficacy and Safety of Basal-Prandial Treatment with Lantus(R) and Apidra(R)